Top Markets
Coin of the day
Pharmanutra S.p.A. Pharmanutra S.p.A.

Pharmanutra S.p.A.

PHN
Rank in Stocks #9895
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise,... Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
Share Price
$97.03
Last synced: 2026-08-28
Market Cap
$929.06M
Change (1 day)
-0.12%
Change (1 year)
70.33%
Country
IT
Trade Pharmanutra S.p.A. (PHN)

Category

P/B ratio for Pharmanutra S.p.A. (PHN)
P/B ratio as of 2026 TTM: 0
According to Pharmanutra S.p.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Pharmanutra S.p.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors